Equities researchers at SunTrust Banks, Inc. assumed coverage on shares of Orthofix International NV (NASDAQ:OFIX) in a report released on Tuesday. The firm set a “buy” rating and a $49.00 price target on the medical device company’s stock. SunTrust Banks, Inc.’s price objective would suggest a potential upside of 17.42% from the company’s previous close.
Separately, Zacks Investment Research downgraded Orthofix International NV from a “hold” rating to a “sell” rating in a research note on Tuesday, May 9th.
Orthofix International NV (NASDAQ:OFIX) opened at 41.73 on Tuesday. The firm has a 50-day moving average price of $39.36 and a 200-day moving average price of $37.65. The firm’s market cap is $752.98 million. Orthofix International NV has a 1-year low of $32.51 and a 1-year high of $48.25.
Orthofix International NV (NASDAQ:OFIX) last released its quarterly earnings results on Thursday, May 4th. The medical device company reported $0.27 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.27. The business had revenue of $102.70 million during the quarter, compared to the consensus estimate of $97.17 million. Orthofix International NV had a return on equity of 9.01% and a net margin of 2.41%. The company’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.28 EPS. On average, analysts expect that Orthofix International NV will post $1.52 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Orthofix International NV (OFIX) Now Covered by SunTrust Banks, Inc.” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://sportsperspectives.com/2017/05/23/orthofix-international-nv-ofix-now-covered-by-suntrust-banks-inc.html.
Several institutional investors have recently made changes to their positions in OFIX. Pacad Investment Ltd. increased its position in shares of Orthofix International NV by 150.0% in the fourth quarter. Pacad Investment Ltd. now owns 3,000 shares of the medical device company’s stock worth $109,000 after buying an additional 1,800 shares during the last quarter. Mason Street Advisors LLC purchased a new position in Orthofix International NV during the first quarter valued at approximately $159,000. Quantbot Technologies LP purchased a new position in Orthofix International NV during the first quarter valued at approximately $175,000. BNP Paribas Arbitrage SA increased its position in Orthofix International NV by 68.9% in the first quarter. BNP Paribas Arbitrage SA now owns 4,656 shares of the medical device company’s stock valued at $178,000 after buying an additional 1,900 shares during the last quarter. Finally, Capstone Asset Management Co. purchased a new position in Orthofix International NV during the first quarter valued at approximately $204,000. Hedge funds and other institutional investors own 94.23% of the company’s stock.
About Orthofix International NV
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Ratings for Orthofix International NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International NV and related companies with MarketBeat.com's FREE daily email newsletter.